In an article titled "Statins and the Risk of Dementia" published in the November 11, 2000, issue of Lancet, Jick and colleagues1 from Boston, Mass, reported an epidemiologic, observational, nested case-control study of subjects enrolled in the United Kingdom-based General Practice Research Database. Records of patients aged 50 to 89 years were classified into 1 of 3 groups: group 1 comprised individuals who received at least 1 prescription of lipid-lowering agents (LLAs) within the previous 6 months; group 2, all individuals with a clinical diagnosis of untreated hyperlipidemia; and group 3, a randomly selected group of other individuals.